Abbvie and partner Enanta Pharmaceuticals have tucked a Breakthrough Therapy label under their belts. The FDA granted the expedited review status Friday to the experimental hepatitis C treatment that includes protease inhibitor ABT-450 and ombitasvir and dasabuvir, with or without the interferon ribavirin.

The all-oral’s progress means the FDA will review the drug within six months, and that AbbVie deposited an additional milestone payment into Enanta’s accounts.